comparemela.com

Latest Breaking News On - Hedge funds weigh in on deciphera pharmaceuticals - Page 1 : comparemela.com

Deciphera Pharmaceuticals (NASDAQ:DCPH) Rating Reiterated by Guggenheim

Guggenheim reaffirmed their neutral rating on shares of Deciphera Pharmaceuticals (NASDAQ:DCPH – Free Report) in a research report sent to investors on Tuesday, Benzinga reports. Other analysts have also recently issued research reports about the company. Jonestrading restated a hold rating and set a $25.60 target price on shares of Deciphera Pharmaceuticals in a report […]

Deciphera Pharmaceuticals (NASDAQ:DCPH) Rating Reiterated by Jonestrading

Jonestrading restated their hold rating on shares of Deciphera Pharmaceuticals (NASDAQ:DCPH – Free Report) in a research note issued to investors on Monday morning, Benzinga reports. Jonestrading currently has a $25.60 price objective on the stock. Several other research firms also recently weighed in on DCPH. JPMorgan Chase & Co. lifted their target price on […]

Deciphera Pharmaceuticals, Inc to Post FY2026 Earnings of ($1 25) Per Share, Zacks Research Forecasts (NASDAQ:DCPH)

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Free Report) – Zacks Research issued their FY2026 earnings per share estimates for Deciphera Pharmaceuticals in a research note issued to investors on Tuesday, February 27th. Zacks Research analyst A. Chakraborty anticipates that the company will post earnings per share of ($1.25) for the year. The consensus estimate for Deciphera […]

Q1 2024 EPS Estimates for Deciphera Pharmaceuticals, Inc (NASDAQ:DCPH) Boosted by HC Wainwright

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Free Report) – Research analysts at HC Wainwright raised their Q1 2024 EPS estimates for Deciphera Pharmaceuticals in a report issued on Wednesday, February 7th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($0.63) per share for the quarter, up from their previous estimate […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.